HR Execs on the Move

MDS Pharma Services

www.mdsps.com

 
A global contract research organization (CRO) that offers a full spectrum of resources to meet the drug discovery and drug development needs of the pharmaceutical and biotechnology industries. With facilities in more than 23 countries, MDS Pharma Servi...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.mdsps.com
  • 621, Rose St
    Lincoln, NE USA 68502
  • Phone: 610.239.7900

Executives

Name Title Contact Details

Similar Companies

Fievet Pharmacy Inc

Fievet Pharmacy Inc is a Washington, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clyde Chemists

Clyde Chemists is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Huyabio

HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.

TechLab

TechLab is a Blacksburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.